Pupillometry responses may serve as biomarkers for depression, provide treatment indications

News
Article

The findings come from a collaborative study between investigators at the Max Planck Institute of Psychiatry, Munich and the Department of Cognitive Sciences, University of California, Irvine

A woman sits in a dark room, looking sadly at the floor.

The study authors pointed out the current absence of biomarkers for major depressive disorder. Image credit: ©StockPhotoPro – stock.adobe.com

A collaborative study between investigators at the Max Planck Institute of Psychiatry, Munich, Germany, and the Department of Cognitive Sciences, University of California, Irvine, United States, found that the usefulness of pupillometry as a clinical test may lie in its ability to identify a specific subgroup of patients with anticipatory hypo-arousal subserving anhedonia symptomatology,1 which may serve as a biomarker of depression.

Led by Andy Brendler, a researcher at the Max Planck Institute of Psychiatry, the group of authors pointed out the current absence of biomarkers for major depressive disorder.

In their study, the investigators analysed a replication sample of 40 unmedicated patients diagnosed with depression that was not treated and 30 healthy controls. The participants performed a reward anticipation task during which their pupillary responses were measured.

Dr Brendler and associates explained that there has been recent interest in the pupillary response, some of which includes the following studies.“The pupillary light reflex, which is an index of pupil size in response to light, characterised by an immediate constriction followed by a dilation,2 is altered in depression. It was observed that patients with a MDD diagnosis had an attenuated constriction velocity3 and an overall lower constriction change4-6 of the pupil in response to light stimuli relative to control participants,” the authors reported.

Findings associated with changes in pupillometry responses

The investigators identified a negative correlation between pupillary dilation and symptom load during reward anticipation in patients diagnosed with major depressive disorder. When the study data were analysed from all 136 participants (ie, 81 unmedicated depressed and 55 healthy control participants), the investigators reported that “reduced pupil dilation in anticipation of reward is inversely associated with anhedonia items of the Beck Depression Inventory in particular.”

In addition, functional magnetic resonance imaging performed simultaneously showed that the right anterior insula as part of the salience network was negatively correlated with depressive symptom load in general and anhedonia items specifically.

This may provide valuable information for treatment allocation and examining the early treatment response. The finding of less pupillary response in patients with depression has implications in treatment.

“Considering that an estimated 30% of depressive patients do not improve using the currently available medications, understanding the physiological mechanisms behind depression and fine-tuning diagnosis and treatment accordingly [are] urgently required,” the authors said.

In discussing their findings, the investigators expressed confidence that the anticipatory hypo-arousal identified by pupillometry is correlated with the depressive symptom load in patients with major depressive disorder. They also believe the study provided “evidence that certain depressed patients can be characterised by anticipatory hypo-arousal assessed by decreased pupil dilation during reward anticipation, with specificity for anhedonia and lack of energy-related items.”

This led them to conclude that pupillometry has value as a clinical test to identify a specific subgroup of patients with anticipatory hypo-arousal subserving anhedonia symptomatology. In addition, this may be valuable when considering treatments in individual patients.

References

  1. Brendler A, Schneider M, Elbau IG, et al. Assessing hypo-arousal during reward anticipation with pupillometry in patients with major depressive disorder: replication and correlations with anhedonia. Sci Rep. 2024;14:344; https://doi.org/10.1038/s41598-023-48792-0
  2. Hall CA, Chilcott RP. Eyeing up the future of the pupillary light reflex in neurodiagnostics. Diagnostics. 2018;8.
  3. Mestanikova A, Ondrejka I, M. Mestanik M, et al. Pupillary light reflex is altered in adolescent depression. Physiol Res. 2017;66:S277–S284.
  4. Laurenzo SA, Kardon R, Ledoltr J, et al. Pupillary response abnormalities in depressive disorders. Psychiat Res. 2016;246:492–499.
  5. Wang J, Fan Y, Zhao, X, Chen N. Pupillometry in Chinese female patients with depression: A pilot study. Int J Environ Res Public Health. 2014;11:2236–2243.
  6. Sekaninova N, Ondrejka I, Bona Olexova L, et al. Oculometric behavior assessed by pupil response is altered in adolescent depression. Physiol Res. 2019;68:S325–S338.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
Related Content
© 2025 MJH Life Sciences

All rights reserved.